JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - EMERGENT BIOSOLUTIONS INC
Good morning, everyone. I'm Joe Papa, happy to be here today to present with Emergent Biosolutions. Emergent Biosolutions is a 26-year-old company, a company that has a very unique health care business model. We partner with governments around the world to handle some of the most difficult biodefense issues, and we're delighted to be able to continue to make progress in this area to combat major public health threats. We have a slide presentation that I'll refer to that also has some forward-looking comments that will refer you to our risk factors in our SEC filings. We have a very experienced and diverse management team that has over 100 years of experience. We have different parts of the business that have had different parts working with many different companies around the pharmaceutical health care space. Delighted to have the opportunity to represent Emergent today and talk about the products that we make and how we do this and what we do each and every day. Let me start with a little bit about the product area and what's specifically important to us. We make products that are very difficult to make. They have significant barriers to entry. For example, there's limited access to the raw materials in cases. For example, one does not want to make sure that anthrax spores are widely available. So I could feel pretty comfortable, for example, that there's no one running to the garage this evening to make a product for an anthraxa vaccine because of the limited availability of the spores. And obviously, governments around the world want to makes sure that spores, anthraxe spores would not fall in the hands of the wrong people or bad actors. So it's an important part of what we do in terms of making difficult-to-make products, but also products that have significant barriers to entry. Let me talk about each of them. For example, the number one biodefense worry in the viral space is smallpox. We make products for smallpox, for the treatment of smallpox and also vaccine for prevention of small pox. Once again, this is the most serious viral threat, and we are there to be prepared with products for littlepox. The number one bacterial threat? Anthrax. We make products for anthrax, we make vaccines for it, we make a therapeutic product for anthRAX, so we're working very diligently with governments around the world. And we, in fact, we know that in many cases, many of the forward deployed troops of the U.S. and other countries will also get vaccination for anthRX because of the concern for this particular bacterial threat. We make products for the number one most lethal toxin, that's botulism, and we have a botulist antitoxin product. So clearly you can see that we're going after products with very significant barriers to entry and products that are difficult to make as part of our portfolio. We also make a product for Ebola. You've probably seen in the news some of the difficult issues we face with Ebola in Africa. There's outbreaks almost every year in Africa. We make a product called Ibanga for the treatment of Ebola. So once again, continuing that theme of products that are important therapeutic agents to help in the prevention and treatment of these very significant diseases. We also have a product for opioid overdoses. We have the leading product called Narcan. It is the brand leader, and that's obviously an important one for trying to reduce the number of opioid overdose deaths, and I'll talk more about that in just a few minutes. This is our strategic manufacturing platform. We have essentially three hub areas. We have our Lansing, Michigan facility. It's predominantly working on products for anthrax. We have the Winnipeg facility. It's mostly a plasma purification area where we've got products from the Winnepeg facility. And then we have our Canton, Massachusetts facility. That's where we make our ACAM product. And I'm delighted to say we just added a new product there, our Japanese encephalitis virus vaccine that we're partnering with Substifar about. And then we've got two other facilities, Rockville, that would make our ACAM fill finish. And then, we have an access to a facility, a very significant facility in Bayview, outside of the Baltimore area. Once again, a partnership opportunity there. So, a Very Diverse platform. We have streamlined this platform. That was an important part of our turnaround plan is to streamline our facilities so that we make sure we had the capabilities but also make sure that we brought down our cost basis for the future of what we were seeking to do. That brings me to the question of what are we doing as a company in terms of the programs we have in place. We are in the middle of a multi-year turnaround plan. The first part of the plan was, number one, to stabilize the company. We ran into some difficulties in 2023, but we've now corrected those difficulties and worked through cutting down and reducing our cost structures. We've done that now and have significantly improved our operating performance as a company. Number two, after the stabilization phase, it was all about what could we do to invest in the company, invest for growth for the future. And that's really the turnaround phase of our company that we're in as we sit today. We're finding places that we can best invest for the future. What products can we make that are important to governments around the world? And that's really been a focus for us as we sit here today. Long-term, we'll seek for transformation, where we'll look for long-term sustainable, profitable growth for the future, and that's the concept of what we intend to do as a company. All the while looking at where can we help governments with solving public health threats all around the world. It's a very unique business model. In fact, we often will partner with the U.S. government, for example, and when we partner with them, they'll help us with our R&D cost. That allows us to submit products, get them approved by the FDA or regulatory authorities around the World. Once we get the approval, we sell them to the countries for what they need for building their stockpiles for their countries to make sure. One of the things that's unique about our business model is that it's just similar if you think about it as a fire extinguisher. You can't go out and buy a fire distinguisher when you have a problem, a fire in a house. You have to have it ahead of time. You have be prepared, and that's what we do. We help governments to be prepared for these type of issues and make sure we're prepared ahead of time, and that's how our business model works well. I'm going to talk briefly about the quarter that we just finished and announced. It was a good quarter for us. We did $110 million of revenue year to date, $500 million of revenue for the company, adjusted EBITDA for the company at $128 million through the first three quarters. Importantly, one of the things that we focused on is generating cash, we've done a lot to work on the reductions in the working capital structure of our company. So the $122 million of operating cash flow has been generated year to day, we have a stronger balance sheet now. We've got about $176 million of cash and then $226 million of total liquidity. So we've made good progress in what we're doing there as a company in terms of the focus on cash to ensure that we can utilize that cash for both for internal research and development as well as what we are doing from a business development point of view. One of the things that was important to us over the last several years is to reduce our debt structure. We've been able to bring that debt structure down. We had approximately $800 million of debt in 2023 year-end. We brought that down dramatically, and today we sit somewhere in the $500 plus, $515 million range of debt, which was an important metric for us as we were continuing to work to stabilize, turn around, and transform our company. We do have a very focused cost discipline. We think that's an important part of reducing the operating costs of our company. We've been very focused on that as we thought about what needed to be done for the future of our business. Looking at where the business goes, I mentioned there's really two major components. The first one is the biodefense side of the business, or we call it medical countermeasures. We got a number of contracts that we've already shipped year to date and more coming in the rest of the year. We focus on making sure that we provide the products that we need to provide for the U.S. government, but also other governments around the world. And in the last quarter, we shipped to 13 different countries. Historically, our percentage of business that we ship to the U S has been somewhere in the 85% range, about 15% that was shipped outside of the U S. I'm delighted to say that we continue to diversify that. And I think that's important in that what we face is an increasingly dangerous world. We want to make sure that we're helping countries to all be prepared for any of these threats for society. The other area I mentioned was Nalaxone. We have been the leaders of the Narcan Naloxone business. I'll talk a little more about that in a few slides, but we continue to hold that leadership position and market share. We're delighted to be able to continue to make sure that we can help reduce opioid overdose deaths. And the steps we took to make the product available over the counter, we think we're a very important part of making access available for our Narcan product. We most recently announced in our Canton, Massachusetts facility was going to be restarted. We've been working very closely with the state of Massachusetts to ensure that we move forward on all of our programs with the Canton, Massachusetts facility. And we are delighted to have a new partner there to work with to manufacture the Japanese encephalitis virus vaccine. And then finally, we continue to make progress in our R&D pipeline. We believe that Ebola is an important area that we're going to focus on. So we've got our product called Ibanga. But beyond just the Ebola program with Ibanga, we are looking at other opportunities to create a pan-Ebola product so that we treat Ebola across all the strains. The current strain that is in Africa today is unique and different and has not responded to some of the vaccines and therapeutic products. So we believe there's more that we need to do there to define that particular strain and come up, come forward with some additional products for that particular stream. So look to us to have more to say about that. And then finally, one of the other things we're working on is this whole area of AI. How can we help in the world of AI? I think all of us feel that AI is important. It's going to be helpful, very helpful, to make things better, more productive, more efficient, but at the same time we worry about how it could potentially get in the hands of bad actors, and we want to make sure from a point of view of the biodefense world that we help governments to be prepared for any potential downsides of AI. This goes a little more at the AI threats and what we're doing here. Suffice it to say, we're all excited about the future of AI, but at the same time, we don't want AI to fall in the hands of bad actors. Those bad actors get a start to try to weaponize some of the pathogens that could make them more lethal. And we want to make sure that we're working with AI companies to understand what's happening with AI, how people are seeking to weaponized those particular potential pathogens. And importantly, how we can help governments to be prepared for that in the event that some bad actor tries to weaponize any particular areas of pathogens. One of the things that we know is that most recent activities with the U.S. military have shown that, for example, if bad actors want to create chaos, and they try to send a missile or rocket at a U.K. facility or U.N. military base, One of the things that we are able to do is knock those out of the sky, those missiles that are incoming. What that means is that the bad actors are looking and reevaluating what can they do to create chaos in the world. We want to make sure that as they think about looking at the work, you know, bioweapons, that we Are prepared to anticipate potentially what they're doing and, importantly, be ready for with solutions. So we're working very closely with the AI companies. I'm sorry, we're continuing to look to work closely with the AI countries to make sure that we're going to be prepared for that. We have a very strong engagement with U.S. government and other governments around the world. This is a look at the medical countermeasures quarter three revenue of $59 million. We've got some additional awards for Sifendis contracts. We've had 10 contract awards, product orders that have been received here today. And what's important about this business is that we make products for governments around the world, but beyond making the product, we also do the testing for that product. And we test it for stability. We'll test it für potency. Why that's important is that the governments need to continue to give us orders not only to make new product, but to ensure that we have the capabilities to test those products. An easy example, Anthrax. We're doing the making of the new products for AnthraX, but we're also doing testing. Governments don't want many companies to have access to anthrax spores because they're worried about a problem with a leak or, importantly, it falling into the hands of bad actors. For that reason, it gives us a significant barrier to entry to our product portfolio, but also means that we have to keep that facility up and running, which gives the long-term nature of our cash flows because they're continuing to support those sites for us because they know they need that capability for testing for the potency, stability, et cetera. The year-to-date number is 22% of our medical countermeasures biodefense revenues have been from outside the U.S. We think that's an important message on diversification of our Cash Flows and how that helps governments around the world with our products, but also helps us having a very diversified cash flow for the future. The other area that I mentioned at the onset was the area of Narcan and what we are doing to help reduce the number of opioid overdose deaths. I'm delighted to say in March of 2023, we got approval for our product to go over the counter. Why is that important? Unfortunately, a lot of people were dying in 2023. The number of opioid overdose deaths were dramatic. It peaked at somewhere around 82,000 deaths in the United States alone. That's obviously way too many deaths. Because we were able to make our product available over-the-counter, it could be more accessible. The issue with opioid overdose is that once you overdose on an opioid, you'll stop breathing. Once you stop breathing, you only have four, five, six minutes at most to make sure you rescue that person or else they will die. So having the product be available over the counter, more accessible, we think has been a big part of reducing that opioid overdose deaths to almost half of where it was just a couple years ago. Now, there have been other initiatives, to be clear, but we believe the availability of our product as an over-the-counter product has been an important part of producing those deaths. And we're trying not just to make it available for the college students that potentially may inadvertently overdose, but also for the construction worker that gets injured on the job. Once they're injured onthe job, they get a prescription, theyget opioids, and it helps. Having said that, they may need and become addicted to the opioid, and they can't get it from the doctor anymore, so they'll go to the street drug. The street drugs aren't done by the best scientists, and unfortunately sometimes they'll get too much of an opioid, a fentanyl, for example, car fentanyl that causes a potential overdose situation so we want to make sure that our products available in different places so for example in a home building supply house where they're the construction may overdose we want make sure it's available there we want to make it's in libraries other places so that once again the theme being the access will reduce the number of deaths. We make two products. We make our product for Narcan, the 4-milligram. It is the gold standard of what we are doing in terms of opioid overdose deaths. So we have our Narcan 4-millimeter product. But we also license in from HICMA a Cloxato 8-milligram nasal spray product. And that's, we think, an important addition, especially now that we know there's more and more people out there that unfortunately are getting exposed to fentanyl. fentanyl is a very potent opioid so we want to make sure we have both the four milligram gold standard but then also the eight milligram sense where it is needed we have also secured some significant government funding of our Narcan program in Canada that's an important part of what we're doing to continue to make that we're available and making the products most accessible that we can because the access will reduce deaths I'm going to just quickly touch on some of the third quarter financial results and full-year guidance. You can see $500 million of year-to-date and $128 million of adjusted EBITDA. We're excited about being able to generate those types of numbers and then, importantly, what that has meant for our gross margins and also reducing operating expenses as a company. Also, this looks at what we've done on the balance sheet point of view from a cash and liquidity point of vue. You can see we're sitting with $176 million of cash and about $50 million of a revolver, so $226 million. That's an important part as we think about the future from a business development point of view. One of the important comments I've made just versus a year ago is we continue to reduce our total debt, material debt reduction. It came down from $693 a year a go down to $514 million, and the net debt down to$339 million. and our leverage is somewhere around 2.4 times. And as I mentioned before, strong operating cash flow in the business, predominantly because of some of the steps we've taken to reduce our working capital as a company. This is a slide that goes back a couple of years, but I think it says an important message about how we have been successful in reducing the debt of our company, bringing it from $868 million in 2023 down to $514 million in the last couple of year. that's been predominantly through the operating performance of the business but also making some decisions to divest some facilities while still ensuring we had the operating manufacturing platform to make all of our products. Year-to-date capital allocations what's it been about it's our turnaround plan is all focused on how can we invest for the future what areas can we go after for growth those areas are items that we're looking at what can we do with what we need to invest in expanding our international platform by having more capabilities outside of the U.S., what we can do with the internal R&D programs, programs that we have. Just, for example, made another $50 million investment in our Ibanga milestone program and other business development opportunities, all focused on growth. On the debt management side, I mentioned how important that's been to us to reduce the overall risk of our company. So we have significantly reduced the total quantum of debt that we have as well as extending the maturities of our debt. And then just most recently we reduced the debt by just another $75 million by looking at unsecured bonds and repaying those and reacquiring those bonds, an important part of what we've done. And we have reauthorized a $50 million share repurchase program through March of 2027, all designed to look at how best to utilize capital we have for the company. This just looks quickly. I won't go through the numbers here of our revenue and profitability guidance, but suffice to say we continue to make progress as a company, and we're continuing to look At what's the revenue going to look like for the future, both on the MCA and commercial side, and then how can we look at our gross margin adjusted EBITDA as we think about the business for our company. Finally, if I just look at catalysts for growth and what we're trying to do, this is just one slide that tries to summarize the programs we have in place. We are looking at organic growth. How can we grow our products? Tembexa, for example, is a therapeutic for smallpox. Raxibacumab is a therapy for anthrax. And then Ibanga is a therapeutics for Ebola. trying to focus on areas that we can add value to the company by helping solve some of these major public health threats around the world. The other thing that's important to us is we know that it's an increasingly dangerous world out there. How can we help look at what we're doing with the U.S. business, and how can we helps solve some the rest of the issues that are faced outside of the U S. to ensure that they're also prepared. And then additionally looking at opportunities, for example, with our Narcan. We know that Narcan is needed by the first responders. They also like this concept of multi-packs where they get by six or 24 products at the same time. It just helps them in terms of their making it more ecological, but also from a packaging point of view, but also make it more efficient for them. We're also making sure we have a carrying case that just clips onto the backpack of a student to make sure that they have the product and they can help support one of their other classmates, et cetera, if anyone gets into difficulty. And then finally, looking at what can we do to grow through business development. The program that we have for ImageEv is just one example we did this year. We're looking to help on the question of Japanese encephalitis virus vaccine. And we'll look to do more of those as we face the rest of this year and into next year. This is just a quick look at the pipeline. Suffice to say, most of our products are either approved or on the progress to get additional validation for the products that we're working on to either scale them up or to make sure that we have a very efficient supply chain for the product. We've got a number of products I mentioned in the image of that I talked about, Substant Farm and partnering with them, or Japanese Encephalitis. We've Got a couple additional undisclosed products, and then we have this Pan-Ebola program that I just talked about. We're delighted to say we just partnered to have some additional leads for the program in the pan-Ebola. And we also have a pandemic flu program that we're looking at. So a number of things all designed to try to look at the most difficult, challenging public health threats and make sure that we are helping society be prepared. And then finally, just quickly, where are we? We continue to make progress in our multi-year turnaround program. I'm delighted to say we've stabilized the company. I'm glad to say that we are investing for the future of our company, and we'll continue to make additional investments as we look to build toward transformation, which for us is all about long-term, sustainable, and profitable growth for the company We have continued to partner with AI leaders. We think that's something that's important. We believe AI is a great tool, but we don't want it to fall in the hands of a bad actor. We'll try to use it to create new pathogens that could help, I'm sorry, that could be very significant concern to societies around the world. We want to make sure we're able to help to anticipate and look at the early diagnostics, but importantly, be able to have products that can treat. We're delighted with what we're doing on Nalaxone. Reducing the deaths has been an important part of what we do as a company. Having said that, there's still a lot more we need to do, and there's still 40-plus thousand people dying from opioid overdose deaths in the United States alone, additional numbers in Canada. We want to make sure that we're helping to continue to bring that death rate down to zero. So look to us to talk more about things that we'll do in that category while we're pursuing different growth initiatives that drive shareholder value, all the time thinking about how important quality is, how important patient safety and compliance is as a company. So that concludes why we believe Emergent is a unique healthcare business model and one that we think provides important products to consumers around the world, especially in the area of preparedness and reducing opioid overdose deaths. Thank you very much for your time today. Appreciate it.
- Company
- EMERGENT BIOSOLUTIONS INC
- Keywords
- EMERGENT BIOSOLUTIONS INC